Aptamer Sciences Submits New Drug Application for Groundbreaking Hepatocellular Carcinoma Therapy AST-201: A Potential Solution for Unmet Treatment Requirements.

Novo Nordisk has entered into an acquisition agreement with Cardior Pharmaceuticals, with the deal amounting to a maximum of 1.025 billion Euros.

Apogee Therapeutics has initiated dosing of initial volunteers in a Phase 1 study of their new extended-duration IL-4Rα antibody, APG808, aimed at managing Chronic Obstructive Pulmonary Disease (COPD) and various inflammatory conditions.

Regeneron Pharmaceuticals, Inc. has declared the receipt of Complete Response Letters from the U.S. Food and Drug Administration concerning their submitted Biologics License Application for the drug odronextamab.

Rhythm Pharma Initiates First Human Dosing in Early-Stage Study of RM-718, a Once-Weekly Compound Targeting MC4R Receptors.

US FDA grants Bio-Thera Solutions approval to start Phase II trial of BAT8006, a novel ADC aimed at Folate Receptor alpha.

AbbVie Plans to Take Over Landos Biopharma, Enhancing Its Collection of Treatments for Inflammation and Autoimmunity.

Ferrer and Verge Genomics have entered into a collaboration to jointly advance the experimental treatment for ALS, designated as VRG50635, into clinical trials.

Astria Therapeutics Reveals Encouraging Early Findings in ALPHA-STAR Phase 1b/2 Study for HAE with STAR-0215.

Ultomiris receives US green light to treat adult patients with spectrum disorder related to neuromyelitis optica (NMOSD).

U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH).

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101.